Gamida Cell’s $60 Million Follow-On Offering

Davis Polk advised the representatives of the underwriters in connection with the offering.

Gamida Cell Ltd. completed the $60 million SEC-registered follow-on offering of ordinary shares. In addition, Gamida Cell has granted the underwriters a 30-day option to purchase up to an additional 2,000,000 ordinary shares at the public offering price, less the underwriting discounts and commissions.

Gamida Cell intends to use the net proceeds from this offering, together with its existing cash and cash equivalents, available for sale and short-term deposits: to fund (i) the preparation of a Biologics Licensing Application for omidubicel in high-risk hematologic malignancies; (ii) the continued clinical development of its product candidates; (iii) the expansion of its commercial manufacturing capabilities; and (iv) general corporate purposes, including general and administrative expenses and working capital.

Piper Sandler & Co. and Evercore Group L.L.C. acted as joint book-running managers for this offering. JMP Securities LLC acted as lead manager for this offering.

Based in Jerusalem, Israel, Gamida Cell is an advanced cell therapy company committed to finding cures for patients with blood cancers and serious blood diseases.

The Davis Polk corporate team included partner Derek Dostal (Picture) and associates Gil Savir and Stephen H. Karp. The intellectual property and technology transactions team included partner David R. Bauer and associate Jesse L. Hallock. Counsel Marcie A. Goldstein provided FINRA advice.

Involved fees earner: David Bauer – Davis Polk & Wardwell; Derek Dostal – Davis Polk & Wardwell; Marcie Goldstein – Davis Polk & Wardwell; Jesse Hallock – Davis Polk & Wardwell; Stephen Karp – Davis Polk & Wardwell; Gil Savir – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Evercore Inc.; JMP Securities LLC; Piper Sandler;

Author: Ambrogio Visconti